A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 580 participants.
Also called NCT05582395
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 580 participants
- Sponsor
- Registry
-
NCT05582395 -
U1111-1269-8581 -
2023-506352-24
-
- Other papers using this trial's data
- Effects of Mavacamten on Cardiac Biomarkers in Nonobstructive Hypertrophic Cardiomyopathy: Insights From the ODYSSEY-HCM Trial
- Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Australia, Austria, Belgium, Brazil, Canada, China, Czechia, Denmark, France, Germany, Hungary, India, Israel, Italy, Japan, Netherlands, Norway, Poland, Portugal, South Korea, Spain, United Kingdom
- Registry status
- Terminated
Technical summary
Registry record NCT05582395. Randomized; double masking; primary purpose treatment. Start 2022-12-14 (actual); primary completion 2025-03-06 (actual). Results posted on 2026-08-20.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy
- Acronym
- ODYSSEY-HCM
- Condition
- Cardiomyopathy, Hypertrophic
- Intervention (Drug)
- Mavacamten
- Intervention (Other)
- Placebo
- Lead sponsor
- Bristol-Myers Squibb
Record details
- Record id
cardio:ct-nct05582395- Content hash
309e235e57ac4abd803db3ddc1921c47911d6169313da4311d1b03003f782d6e